{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T03:03:25Z","timestamp":1777604605549,"version":"3.51.4"},"reference-count":89,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T00:00:00Z","timestamp":1720915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Vascular invasion of hepatocellular carcinoma involves tumor plugs in the main trunk of the portal vein, bile ducts, and veins, and it indicates poor prognosis. It is often associated with portal hypertension, which requires evaluation and management. Treatment includes hepatic resection, systemic pharmacotherapy, hepatic arterial infusion chemotherapy, and radiation therapy. Recurrence rates post-hepatic resection are high, and systemic drug therapy often has limited therapeutic potential in patients with a poor hepatic reserve. Single therapies are generally inadequate, necessitating combining multiple therapies with adjuvant and systemic pharmacotherapy before and after hepatectomy. This narrative review will provide an overview of the treatment of hepatocellular carcinoma with vascular invasion.<\/jats:p>","DOI":"10.3390\/cancers16142534","type":"journal-article","created":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T08:35:17Z","timestamp":1721032517000},"page":"2534","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The Treatment of Hepatocellular Carcinoma with Major Vascular Invasion"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9975-386X","authenticated-orcid":false,"given":"Tomoko","family":"Tadokoro","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki, Kita, Takamatsu 761-0793, Kagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8801-2505","authenticated-orcid":false,"given":"Joji","family":"Tani","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki, Kita, Takamatsu 761-0793, Kagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0760-3045","authenticated-orcid":false,"given":"Asahiro","family":"Morishita","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki, Kita, Takamatsu 761-0793, Kagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki, Kita, Takamatsu 761-0793, Kagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Masaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki, Kita, Takamatsu 761-0793, Kagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Kobara","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki, Kita, Takamatsu 761-0793, Kagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Dalzell, C.G., Taylor, A.C., and White, S.B. (2023). New Insights on Liver-Directed Therapies in Hepatocellular Carcinoma. Cancers, 15.","DOI":"10.3390\/cancers15245749"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.gassur.2005.12.011","article-title":"Resection of hepatocellular carcinoma with tumor thrombus in the major vasculature. A European case-control series","volume":"10","author":"Hardwigsen","year":"2006","journal-title":"J. Gastrointest. Surg."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1159\/000327577","article-title":"Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version","volume":"29","author":"Kudo","year":"2011","journal-title":"Dig. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.surg.2018.06.025","article-title":"Growth velocity of the portal vein tumor thrombus accelerated by its progression, alpha-fetoprotein level, and liver fibrosis stage in patients with hepatocellular carcinoma","volume":"164","author":"Gon","year":"2018","journal-title":"Surgery"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1055\/s-2007-1007122","article-title":"Prognosis of hepatocellular carcinoma: The BCLC staging classification","volume":"19","author":"Llovet","year":"1999","journal-title":"Semin. Liver Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.hbpd.2021.12.004","article-title":"Management of hepatocellular carcinoma patients with portal vein tumor thrombosis: A narrative review","volume":"21","author":"Tao","year":"2022","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1002\/hep.30490","article-title":"An eastern hepatobiliary surgery hospital\/portal vein tumor thrombus scoring system as an aid to decision making on hepatectomy for hepatocellular carcinoma patients with portal vein tumor thrombus: A multicenter study","volume":"69","author":"Zhang","year":"2019","journal-title":"Hepatology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hep.510290145","article-title":"Natural history of untreated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials","volume":"29","author":"Llovet","year":"1999","journal-title":"Hepatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jus.2008.12.004","article-title":"Radiofrequency ablation of hepatocellular carcinoma extended into the portal vein: Preliminary results","volume":"12","author":"Giorgio","year":"2009","journal-title":"J. Ultrasound"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/hepr.13892","article-title":"Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH-HCC Guidelines)","volume":"53","author":"Hasegawa","year":"2023","journal-title":"Hepatol. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.jhep.2016.05.044","article-title":"Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion","volume":"65","author":"Kokudo","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ejso.2017.11.022","article-title":"The role of liver resection in the management of intermediate and advanced stage hepatocellular carcinoma. A systematic review","volume":"44","author":"Glantzounis","year":"2018","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"7663","DOI":"10.1245\/s10434-021-09974-0","article-title":"Prognostic Impact of Surgical Intervention After Lenvatinib Treatment for Advanced Hepatocellular Carcinoma","volume":"28","author":"Shindoh","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1159\/000515554","article-title":"Comparison of Surgical Resection and Systemic Treatment for Hepatocellular Carcinoma with Vascular Invasion: National Cancer Database Analysis","volume":"10","author":"Govalan","year":"2021","journal-title":"Liver Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(23)01796-8","article-title":"Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): A randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jhep.2012.06.014","article-title":"Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial","volume":"57","author":"Bruix","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma","volume":"379","author":"Meyer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.2021.39.15_suppl.4073","article-title":"IMbrave150: Exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients (pts) with main trunk and\/or contralateral portal vein invasion (Vp4) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in a global Ph III study","volume":"39","author":"Breder","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_25","first-page":"EVIDoa2100070","article-title":"Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma","volume":"1","author":"Lau","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.29486","article-title":"Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease: A systematic review and meta-analysis","volume":"67","author":"Finn","year":"2018","journal-title":"Hepatology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"696","DOI":"10.5009\/gnl.2013.7.6.696","article-title":"Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis","volume":"7","author":"Jeong","year":"2013","journal-title":"Gut Liver"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.21873\/anticanres.14193","article-title":"Sorafenib vs. Lenvatinib as First-line Therapy for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis","volume":"40","author":"Kuzuya","year":"2020","journal-title":"Anticancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/hepr.13511","article-title":"Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria","volume":"50","author":"Sho","year":"2020","journal-title":"Hepatol. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.1158\/1078-0432.CCR-23-1462","article-title":"A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study","volume":"29","author":"Kobayashi","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1159\/000507022","article-title":"Potential of Lenvatinib for an Expanded Indication from the REFLECT Trial in Patients with Advanced Hepatocellular Carcinoma","volume":"9","author":"Maruta","year":"2020","journal-title":"Liver Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Kudo, M. (2021). Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination Therapy. Cancers, 13.","DOI":"10.3390\/cancers13215475"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s43018-022-00357-2","article-title":"Molecular pathogenesis and systemic therapies for hepatocellular carcinoma","volume":"3","author":"Llovet","year":"2022","journal-title":"Nat. Cancer."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11523-023-01026-9","article-title":"Tremelimumab: A Review in Advanced or Unresectable Hepatocellular Carcinoma","volume":"19","author":"France","year":"2024","journal-title":"Target. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.3748\/wjg.v21.i13.3843","article-title":"Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma","volume":"21","author":"Song","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamaoncol.2019.0250","article-title":"Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma with Portal Vein Invasion: A Randomized Clinical Trial","volume":"5","author":"He","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Iwamoto, H., Niizeki, T., Nagamatsu, H., Ueshima, K., Nomura, T., Kuzuya, T., Kasai, K., Kooka, Y., Hiraoka, A., and Sugimoto, R. (2021). Survival Benefit of Hepatic Arterial Infusion Chemotherapy over Sorafenib in the Treatment of Locally Progressed Hepatocellular Carcinoma. Cancers, 13.","DOI":"10.3390\/cancers13040646"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jhep.2023.09.010","article-title":"Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis","volume":"80","author":"Colapietro","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Tadokoro, T., Nomura, T., Fujita, K., Manabe, T., Takuma, K., Nakahara, M., Oura, K., Mimura, S., Tani, J., and Morishita, A. (2024). Management of hepatocellular carcinoma, an important cause of death in Japanese autoimmune hepatitis patients. BMC Gastroenterol., 24.","DOI":"10.1186\/s12876-024-03204-z"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3892\/mco.2014.259","article-title":"Clinical characteristics and prognostic factors for advanced hepatocellular carcinoma with extrahepatic metastasis","volume":"2","author":"Aino","year":"2014","journal-title":"Mol. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Kim, J.H., Nam, H.C., Kim, C.W., Cho, H.S., Yoo, J.S., Han, J.W., Jang, J.W., Choi, J.Y., Yoon, S.K., and Yang, H. (2023). Comparative Analysis of Atezolizumab Plus Bevacizumab and Hepatic Artery Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multicenter, Propensity Score Study. Cancers, 15.","DOI":"10.3390\/cancers15174233"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/bjc.2013.542","article-title":"Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan","volume":"109","author":"Nouso","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1159\/000508724","article-title":"Hepatic Arterial Infusion Chemotherapy versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma","volume":"9","author":"Ueshima","year":"2020","journal-title":"Liver Cancer"},{"key":"ref_45","first-page":"1013","article-title":"Clinical effects and safety of intra-arterial infusion therapy of cisplatin suspension in lipiodol combined with 5-fluorouracil versus sorafenib, for advanced hepatocellular carcinoma with macroscopic vascular invasion without extra-hepatic spread: A prospective cohort study","volume":"7","author":"Nakano","year":"2017","journal-title":"Mol. Clin. Oncol."},{"key":"ref_46","first-page":"447","article-title":"Efficacy of combined modality therapy with sorafenib following hepatic arterial injection chemotherapy and three-dimensional conformal radiotherapy for advanced hepatocellular carcinoma with major vascular invasion","volume":"11","author":"Nomura","year":"2019","journal-title":"Mol. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1200\/JCO.21.01963","article-title":"Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1)","volume":"40","author":"Lyu","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ijrobp.2023.08.015","article-title":"Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Meta-Analysis and International Stereotactic Radiosurgery Society Practice Guidelines","volume":"118","author":"Bae","year":"2024","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1200\/JCO.2015.61.4925","article-title":"Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma","volume":"34","author":"Wahl","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Ishida, T., Mizumoto, M., Saito, T., Okumura, T., Miura, K., Makishima, H., Iizumi, T., Numajiri, H., Baba, K., and Murakami, M. (2024). Proton Beam Therapy for Treating Patients with Hepatocellular Carcinoma with Major Portal Vein Tumor Invasion: A Single Center Retrospective Study. Cancers, 16.","DOI":"10.3390\/cancers16112050"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.radonc.2017.11.013","article-title":"Comparison of radiation therapy modalities for hepatocellular carcinoma with portal vein thrombosis: A meta-analysis and systematic review","volume":"129","author":"Rim","year":"2018","journal-title":"Radiother. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S1470-2045(22)00326-6","article-title":"Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): A multicentre, open-label, randomised, phase 3 trial","volume":"23","author":"Kelley","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"W221","DOI":"10.2214\/AJR.09.2852","article-title":"Mass reduction by radiofrequency ablation before hepatic arterial infusion chemotherapy improved prognosis for patients with huge hepatocellular carcinoma and portal vein thrombus","volume":"194","author":"Hirooka","year":"2010","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/hepr.12392","article-title":"Role of 3-D conformal radiotherapy for major portal vein tumor thrombosis combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma","volume":"45","author":"Fujino","year":"2015","journal-title":"Hepatol. Res."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Nakazawa, T., Hidaka, H., Shibuya, A., Okuwaki, Y., Tanaka, Y., Takada, J., Minamino, T., Watanabe, M., Kokubu, S., and Koizumi, W. (2014). Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: Propensity score analysis. BMC Gastroenterol., 14.","DOI":"10.1186\/1471-230X-14-84"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000486483","article-title":"Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis","volume":"94","author":"Kodama","year":"2018","journal-title":"Oncology."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1159\/000513706","article-title":"Hepatic Arterial Infusion Chemotherapy Combined with Radiation Therapy for Advanced Hepatocellular Carcinoma with Tumor Thrombosis of the Main Trunk or Bilobar of the Portal Vein","volume":"10","author":"Kosaka","year":"2021","journal-title":"Liver Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S2468-1253(18)30078-5","article-title":"Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): A randomised, open label, phase 3 trial","volume":"3","author":"Kudo","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Leung, J.H., Wang, S.Y., Leung, H.W.C., and Chan, A.L.F. (2024). Comparative efficacy and safety of multimodality treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: Patient-level network meta-analysis. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1344798"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000531820","article-title":"Multicenter Phase II Trial of Lenvatinib plus Hepatic Intra-Arterial Infusion Chemotherapy with Cisplatin for Advanced Hepatocellular Carcinoma: LEOPARD","volume":"13","author":"Ikeda","year":"2024","journal-title":"Liver Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"100991","DOI":"10.1016\/j.jhepr.2023.100991","article-title":"Concurrent nivolumab and external beam radiation therapy for hepatocellular carcinoma with macrovascular invasion: A phase II study","volume":"6","author":"Kim","year":"2024","journal-title":"JHEP Rep."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Hwang, S.Y., Woo, H.Y., Heo, J., Kim, H.J., Park, Y.J., Yi, K.Y., Lee, Y.R., Park, S.Y., Chung, W.J., and Jang, B.K. (2024). Outcome of Atezolizumab Plus Bevacizumab Combination Therapy in High-Risk Patients with Advanced Hepatocellular Carcinoma. Cancers, 16.","DOI":"10.3390\/cancers16040838"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Li, Y., Guo, J., Liu, W., Pang, H., Song, Y., Wu, S., Zhang, F., Yan, D., Chen, J., and An, C. (2024). Hepatic artery infusion chemotherapy combined with camrelizumab plus rivoceranib for hepatocellular carcinoma with portal vein tumor thrombosis: A multicenter propensity score-matching analysis. Hepatol. Int.","DOI":"10.1007\/s12072-024-10672-8"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"619","DOI":"10.4103\/jcrt.JCRT_1253_20","article-title":"Anlotinib followed by transarterial chemoembolization and radiofrequency ablation is a safe and effective initial treatment for hepatocellular carcinoma patients with portal vein tumor thrombus: A retrospective case series study","volume":"17","author":"Wang","year":"2021","journal-title":"J. Cancer Res. Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1097\/MD.0000000000000364","article-title":"Hepatocellular carcinoma with bile duct tumor thrombus: A clinicopathological analysis of factors predictive of recurrence and outcome after surgery","volume":"94","author":"Zeng","year":"2015","journal-title":"Medicine"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1002\/deo2.265","article-title":"Hepatocellular carcinoma treated with radical resection after endoscopic diagnosis of the extent of bile duct invasion: A case report","volume":"4","author":"Sato","year":"2024","journal-title":"DEN Open"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3350\/cmh.2016.0088","article-title":"Clinical features and outcomes of patients with hepatocellular carcinoma complicated with bile duct invasion","volume":"23","author":"An","year":"2017","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S0002-9610(06)80023-1","article-title":"Management of hepatocellular carcinoma presenting as obstructive jaundice","volume":"160","author":"Lau","year":"1990","journal-title":"Am. J. Surg."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Huang, L.M., Zeng, Z.X., Wu, J.Y., Li, Y.N., Wang, J.X., Fu, Y.K., Wu, J.Y., Wei, S.M., Lv, J.H., and Chen, W.Z. (2023). Surgical outcomes of hepatocellular carcinoma with extrahepatic bile duct tumor thrombus: A multicenter study. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1291479"},{"key":"ref_70","first-page":"257","article-title":"Surgical management in hepatocellular carcinoma with portal vein tumour thrombosis: Is this the end of the road or a chance to expand the criteria for resectability?","volume":"17","author":"Benatatos","year":"2022","journal-title":"Prz. Gastroenterol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1159\/000507051","article-title":"Efficacy and Safety of Sorafenib in Unresectable Hepatocellular Carcinoma with Bile Duct Invasion","volume":"98","author":"Tanaka","year":"2020","journal-title":"Oncology"},{"key":"ref_72","first-page":"332","article-title":"Complete response to tremelimumab plus durvalumab treatment in hepatocellular carcinoma with a bile duct tumor thrombus: A case report","volume":"28","author":"Ishihara","year":"2024","journal-title":"Oncol. Lett."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Iizumi, T., Okumura, T., Hasegawa, N., Ishige, K., Fukuda, K., Seo, E., Makishima, H., Niitsu, H., Takahashi, M., and Sekino, Y. (2023). Proton beam therapy for hepatocellular carcinoma with bile duct invasion. BMC Gastroenterol., 23.","DOI":"10.1186\/s12876-023-02897-y"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Lee, C.H., Chen, A.H., Hung, S.P., Hsieh, C.E., Tseng, J.H., Chen, P.J., Cheng, J.Y., Chang, J.T., Chan, K.M., and Lin, S.M. (2022). Proton Beam Therapy in Managing Unresectable Hepatocellular Carcinoma with Bile Duct Invasion. Cancers, 14.","DOI":"10.3390\/cancers14071616"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Chang, X., Li, X., Sun, P., Li, Z., Sun, P., and Ning, S. (2024). HAIC Combined with lenvatinib plus PD-1 versus lenvatinib Plus PD-1 in patients with high-risk advanced HCC: A real-world study. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-12233-6"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"435","DOI":"10.4297\/najms.2011.3435","article-title":"Intra-atrial tumor thrombi secondary to hepatocellular carcinoma responding to chemotherapy","volume":"3","author":"Vallakati","year":"2011","journal-title":"N. Am. J. Med. Sci."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00270-008-9342-4","article-title":"Transcatheter arterial chemoembolization for advanced hepatocellular carcinoma with inferior vena cava and right atrial tumors","volume":"31","author":"Chern","year":"2008","journal-title":"Cardiovasc. Intervent. Radiol."},{"key":"ref_78","first-page":"4641","article-title":"Clinical characteristics and treatment outcomes of hepatocellular carcinoma with inferior vena cava\/heart invasion","volume":"31","author":"Chun","year":"2011","journal-title":"Anticancer. Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/hep.29225","article-title":"Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: A Japanese nationwide survey","volume":"66","author":"Kokudo","year":"2017","journal-title":"Hepatology"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40477-019-00361-w","article-title":"Hepatocellular carcinoma tumor thrombus entering the inferior vena cava treated with percutaneous RF ablation: A case report","volume":"22","author":"Gatti","year":"2019","journal-title":"J. Ultrasound."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Li, W., Wang, Y., Gao, W., and Zheng, J. (2017). HCC with tumor thrombus entering the right atrium and inferior vena cava treated by percutaneous ablation. BMC Surg., 17.","DOI":"10.1186\/s12893-017-0217-y"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1007\/s00262-020-02845-9","article-title":"Real-world outcome of immune checkpoint inhibitors for advanced hepatocellular carcinoma with macrovascular tumor thrombosis","volume":"70","author":"Tsai","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12957-024-03396-4","article-title":"Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma with macrovascular invasion","volume":"22","author":"Zhang","year":"2024","journal-title":"World J. Surg. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.radonc.2018.02.030","article-title":"External beam radiation therapy to hepatocellular carcinoma involving inferior vena cava and\/or right atrium: A meta-analysis and systemic review","volume":"129","author":"Rim","year":"2018","journal-title":"Radiother. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e26390","DOI":"10.1097\/MD.0000000000026390","article-title":"Clinical outcome and toxicity of radiotherapy for inferior vena cava tumor thrombus in HCC patients: A retrospective study","volume":"100","author":"Lee","year":"2021","journal-title":"Medicine"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Pao, T.H., Hsueh, W.T., Chang, W.L., Chiang, N.J., Lin, Y.J., Liu, Y.S., and Lin, F.C. (2019). Radiotherapy for inferior vena cava tumor thrombus in patients with hepatocellular carcinoma. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5654-9"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ijrobp.2009.07.1730","article-title":"Combination of transarterial chemoembolization and three-dimensional conformal radiotherapy for hepatocellular carcinoma with inferior vena cava tumor thrombus","volume":"78","author":"Koo","year":"2010","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1872-034X.2011.00943.x","article-title":"Hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma in combination with or without three-dimensional conformal radiotherapy to venous tumor thrombosis in hepatic vein or inferior vena cava","volume":"42","author":"Murakami","year":"2012","journal-title":"Hepatol. Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"63","DOI":"10.17998\/jlc.2022.01.18","article-title":"Sorafenib combined with radiation therapy for advanced hepatocellular carcinoma with portal and hepatic vein invasion extending to the inferior vena cava: A complete response case according to modified RECIST criteria","volume":"22","author":"Cho","year":"2022","journal-title":"J. Liver Cancer."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/14\/2534\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:16:33Z","timestamp":1760109393000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/14\/2534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,14]]},"references-count":89,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["cancers16142534"],"URL":"https:\/\/doi.org\/10.3390\/cancers16142534","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,14]]}}}